Pfizer's Cancer Cachexia Breakthrough: A Glimmer of Hope for the Weakest Link
The news of Pfizer's positive midstage trial results for its experimental drug, ponsegromab, has sent shockwaves through the medical community. This monoclonal antibody has shown remarkable promise in combating cancer cachexia, a life-threatening condition that afflicts approximately 9 million peopl